Antibody-drug conjugates (ADCs) are attracting a significant amount of attention as they have the potential to revolutionize cancer treatment. Chemical ligation of cytotoxic agents to monoclonal antibodies allows the selective delivery of cytotoxins to tumor cells thereby potentially mitigating some of the damaging side-effects of cancer chemotherapy. There are currently a number of FDA-approved ADCs and numerous others at varying stages of development. Concept Life Sciences has expertise in all aspects of ADC synthesis and characterization to help expedite your ADC projects from discovery to the clinic.